# First Tracks Biotherapeutics, Inc. (TRAX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/first-tracks-biotherapeutics-inc/ JSON: https://steadybase.io/company/first-tracks-biotherapeutics-inc.json Checked Nov 21, 2026. Latest filing read: Nov 3, 2026.

## Company

- Legal name: First Tracks Biotherapeutics, Inc.
- Ticker: TRAX (Nasdaq)
- SEC CIK: 0002091349
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: San Diego, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Website: firsttracksbio.com
- Investor relations: https://ir.firsttracksbio.com/news-events/news-releases
- LinkedIn: https://www.linkedin.com/company/firsttracksbiotherapeutics
- Next earnings date: Feb 2, 2027

## Key facts

- Shares outstanding: 42,017,901 as of Oct 29, 2026 (10-Q filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526445430/0001193125-26-445430-index.html

## Business

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.com or follow us on LinkedIn .

Source: Press release "About" paragraph, https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/trax-ex99_1.htm

## Officers and directors

- Daniel Faga, President and chief executive officer. Source: 8-K filed Nov 3, 2026, https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-ex99_1.htm
- Ajim Tamboli, Chief Financial Officer. LinkedIn: https://linkedin.com/in/ajim-tamboli. Source: Form 4 filed May 14, 2026, https://www.sec.gov/Archives/edgar/data/2091349/000185568426000008/0001855684-26-000008-index.htm
- Benjamin Stone, Chief Business Officer. LinkedIn: https://linkedin.com/in/benjamin-stone-a2ab4612. Source: Form 4 filed Aug 18, 2026, https://www.sec.gov/Archives/edgar/data/2091349/000212878626000006/0002128786-26-000006-index.htm
- Paul F. Lizzul, Chief Medical Officer. Source: Form 4 filed Aug 18, 2026, https://www.sec.gov/Archives/edgar/data/2091349/000171146226000014/0001711462-26-000014-index.htm

## Recent 8-K events

- Nov 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-20261103.htm
- Oct 20, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526426666/trax-20261019.htm
- Oct 15, 2026: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/trax-20261015.htm
- Oct 13, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526419761/trax-20261012.htm
- Aug 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/trax-20260812.htm
- Jun 22, 2026: Item 1.01, Entry into a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526277504/trax-20260615.htm
- May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/trax-20260514.htm
- Apr 20, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.01, Completion of acquisition or disposition of assets; Item 3.02, Unregistered sales of equity securities; Item 3.03, Material modification to rights of security holders; Item 5.01, Changes in control of registrant; Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703d8k.htm
- Apr 3, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/d111394d8k.htm

## Insider trades (Form 4)

- Sep 2, 2026: J. Anthony Ware (Director) sold 39,265 shares, about $1.8M. Source: https://www.sec.gov/Archives/edgar/data/2091349/000171542926000007/0001715429-26-000007-index.htm

## What management said

- "ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gl" Daniel Faga, president and chief executive officer (8-K filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-ex99_1.htm

## Latest filings

- 8-K filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-20261103.htm
- 10-Q filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/2091349/000119312526445430/trax-20260930.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

